RT Book, Section
A1 Trinkman, Heidi
A1 Beam, Donald
A1 Hagemann, Tracy
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1145204400
T1 Coagulation Disorders
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1145204400
RD 2022/05/18
AB KEY  CONCEPTS  Hemophilia  is  an  inherited  bleeding  disorder  resulting  from  a  congenital  deficiency  in  factor  VIII  or  IX.  The  goal  of  therapy  for  hemophilia  is  to  prevent  bleeding  episodes,  and  as  a  result  their  long-term  complications,  and  to  arrest  bleeding  if  it  occurs.  Recombinant  factor  concentrates  usually  are  first-line  treatment  of  hemophilia  as  they  have  the  lowest  risk  of  infection.  Inhibitor  formation  is  the  most  significant  treatment  complication  in  hemophilia.  It  is  associated  with  significant  morbidity  and  decreased  quality  of  life.  Recombinant  factor  VIIa  is  effective  for  the  treatment  of  acute  bleeds  in  patients  with  hemophilia  A  or  B  that  has  developed  inhibitors.  The  goal  of  therapy  for  von  Willebrand  disease  (vWD)  is  to  increase  von  Willebrand  factor  (vWF)  and  factor  VIII  levels  to  prevent  bleeding  during  surgery  or  arrest  bleeding  when  it  occurs.  Factor  VIII  concentrates  that  contain  vWF  are  the  agents  of  choice  for  treatment  of  type  3  vWD  and  some  type  2  von  Willebrand  disease,  and  for  serious  bleeding  in  type  1  von  Willebrand  disease.  Desmopressin  acetate  often  is  effective  for  treatment  of  type  1  vWD.  It  also  may  be  effective  for  treatment  of  some  forms  of  type  2  vWD  in  addition  to  mild  to  moderate  hemophilia  A.